Appearing as a noteworthy advance in the fight against obesity, this medication is attracting considerable attention . It combines the action of two known GLP-1 binding agonists, dulaglutide , and an unique glucose-dependent incretin component. Initial clinical findings have indicated significant fat reduction in patients with obesity , possibl… Read More